Bohemine
Latest Information Update: 29 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase inhibitors; Cyclin-dependent kinase-activating kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 May 1999 New profile
- 26 May 1999 Preclinical development for Cancer in Czech Republic (Unknown route)